If they rolled KARD into CTIX, then KARD income will now be on CTIX books and the cost of business will now be in house instead of as a separate entity at cost plus.
I am curious to see what the KARD income is in the 10K or next 10Q that reports it. They are a CRO that does contract work for dozens of biopharmas and Big Pharmas. Their profit will now go to cost of drug development.